baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

IMMATICS N.V./ NL0015285941 /

6/13/2024 5:33:06 PM	Chg. -0.1500	Volume	Bid9:59:26 PM	Ask9:59:54 PM	High	Low
12.4000EUR	-1.20%	259 Turnover: 3,211.6000	-Bid Size: -	-Ask Size: -	12.4000	11.9800

GlobeNewswire 5/14 Immatics Announces First Quarter 2024 Financial Results and Business Update

GlobeNewswire 3/21 Immatics Announces Full Year 2023 Financial Results and Corporate Update

Newsfile Corp 2/15 Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments

GlobeNewswire 1/18 Immatics Announces Pricing of $175 Million Public Offering

GlobeNewswire 1/17 Immatics Announces Proposed Public Offering

GlobeNewswire 1/9 PRISM MarketView Honors National Biotechnology Month with a Spotlight on Emerging Biotech Innovators

GlobeNewswire 11/30/2023 Levicept Appoints Eliot Forster as CEO

GlobeNewswire 11/14/2023 Immatics Announces Third Quarter 2023 Financial Results and Business Update

GlobeNewswire 11/8/2023 Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targ...

GlobeNewswire 10/24/2023 Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA20...

GlobeNewswire 9/11/2023 Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology...

GlobeNewswire 8/17/2023 Immatics Announces Second Quarter 2023 Financial Results and Business Update

GlobeNewswire 1/11/2022 Cabaletta Bio Strengthens Executive Leadership Team with Promotions of Gwendolyn Binder, Ph.D. to Pr...

Newsfile Corp 12/14/2021 Awakn Life Sciences Appoints Former EVP & Chief Commercial Officer of Gilead Sciences, Paul Carter, ...

GlobeNewswire 12/14/2021 Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific P...

GlobeNewswire 11/16/2021 Immatics Announces Third Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire 11/9/2021 Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine® IMA203 P...

GlobeNewswire 11/1/2021 Immatics to Present Update on Lead ACTengine® Program IMA203 Targeting PRAME at the Society for Immu...

GlobeNewswire 8/10/2021 Immatics Announces Second Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire 5/26/2021 Immatics Announces Changes to its Board of Directors

GlobeNewswire 5/18/2021 Immatics Announces First Quarter 2021 Financial Results and Business Update

GlobeNewswire 5/11/2021 Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA402 Targeting PRA...

GlobeNewswire 3/30/2021 Immatics Announces Full Year 2020 Financial Results and Corporate Update

GlobeNewswire 3/17/2021 Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs

GlobeNewswire 12/22/2020 Global Kinetics appoints Thomas Ulmer as Chief Financial Officer

IMMATICS N.V./ NL0015285941 /

If you wish to receive reply to your feedback, please provide your email address.